58084-48-3 Usage
General Description
Ergolin-8-amine, 9,10-didehydro-6-methyl-, (8a)- (9CI) is a chemical compound that falls into the class of ergoline alkaloids. It is a derivative of ergoline and has a molecular formula of C16H19N3O. Ergolin-8-amine,9,10-didehydro-6-methyl-, (8a)- (9CI) is known for its psychoactive effects and is structurally similar to natural neurotransmitters in the brain such as serotonin and dopamine. It has been studied for its potential pharmacological properties, particularly in relation to its impact on the central nervous system. Additionally, it has been investigated for its potential use in the treatment of certain disorders, such as Parkinson's disease and migraines.
Check Digit Verification of cas no
The CAS Registry Mumber 58084-48-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,0,8 and 4 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 58084-48:
(7*5)+(6*8)+(5*0)+(4*8)+(3*4)+(2*4)+(1*8)=143
143 % 10 = 3
So 58084-48-3 is a valid CAS Registry Number.
58084-48-3Relevant articles and documents
NOVEL NEUROMODULATORY COMPOUNDS
-
Paragraph 0171, (2013/07/05)
Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein. In other embodiments, provided herein are methods of agonizing dopaminergic D2 receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT2 receptors using the compounds and compositions disclosed herein.
